← Back to Screener
Biohaven Ltd. (BHVN)
Price$10.01
Favorite Metrics
Price vs S&P 500 (26W)-36.38%
Price vs S&P 500 (4W)8.26%
Market Capitalization$1.56B
All Metrics
Book Value / Share (Quarterly)$0.39
P/TBV (Annual)44.49x
Cash Flow / Share (Quarterly)$-4.60
Price vs S&P 500 (YTD)-10.79%
EPS (TTM)$-6.96
10-Day Avg Trading Volume1.92M
EPS Excl Extra (TTM)$-6.96
EPS (Annual)$-6.86
ROI (Annual)-253.92%
Cash / Share (Quarterly)$2.40
ROA (Last FY)-163.66%
EBITD / Share (TTM)$-6.76
ROE (5Y Avg)-487.22%
Cash Flow / Share (Annual)$-4.60
P/B Ratio29.96x
P/B Ratio (Quarterly)28.77x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-27.53x
ROA (TTM)-158.04%
EPS Incl Extra (Annual)$-6.86
Current Ratio (Annual)3.18x
Quick Ratio (Quarterly)2.77x
3-Month Avg Trading Volume2.69M
52-Week Price Return-43.98%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.25
52-Week High$24.06
EPS Excl Extra (Annual)$-6.86
CapEx CAGR (5Y)-23.34%
Tangible BV CAGR (5Y)14.92%
26-Week Price Return-32.40%
Quick Ratio (Annual)2.77x
13-Week Price Return-12.42%
Total Debt / Equity (Annual)4.59x
Current Ratio (Quarterly)3.18x
Enterprise Value$1,568.804
Book Value / Share Growth (5Y)8.49%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.40
3-Month Return Std Dev72.09%
Net Income / Employee (TTM)$-3
ROE (Last FY)-1418.85%
EPS Basic Excl Extra (Annual)$-6.86
Total Debt / Equity (Quarterly)4.59x
EPS Incl Extra (TTM)$-6.96
ROI (TTM)-180.03%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.25
Price vs S&P 500 (52W)-73.81%
Year-to-Date Return-8.15%
5-Day Price Return10.44%
EPS Normalized (Annual)$-6.86
ROA (5Y Avg)-123.49%
Month-to-Date Return22.58%
Cash Flow / Share (TTM)$-6.72
EBITD / Share (Annual)$-6.76
LT Debt / Equity (Annual)4.59x
ROI (5Y Avg)-254.23%
LT Debt / Equity (Quarterly)4.59x
EPS Basic Excl Extra (TTM)$-6.96
P/TBV (Quarterly)44.49x
P/B Ratio (Annual)28.77x
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)-13.10%
Beta3.19x
Revenue / Share (TTM)$0.00
ROE (TTM)-380.17%
52-Week Low$7.48
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.04
4.04
4.04
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BHVNBiohaven Ltd. | — | — | — | — | $10.01 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Biohaven is a clinical-stage biopharmaceutical company developing treatments across immunology, neuroscience, and oncology. Its pipeline targets neuromuscular diseases, metabolic disorders, obsessive-compulsive disorder, and cancer, utilizing multiple therapeutic modalities including glutamate modulators, myostatin inhibitors, ion channel modulators, and antibody-drug conjugates. The company has multiple product candidates spanning these therapeutic areas at various development stages.